Search

Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K

Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Our goal of transforming DLL3-positive carcinomas

Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

Telemedicine – the standalone study that became the new normal

Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Helping a Local Community in a Time of Need

Scam alert

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

OFEV® (nintedanib) Now Available in the United States

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Niha Agarwalla

Diversity

Innovation from within

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis